http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20220045198-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2dfde99b696148d6c84b5dfb50916f23 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-24 |
| filingDate | 2020-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90926f323db4ed973b10727b4a7d19a5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dca03a40ca8638cc87c497527db7c202 |
| publicationDate | 2022-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20220045198-A |
| titleOfInvention | GNRH antagonists for the treatment of estrogen-dependent disorders |
| abstract | The present disclosure provides compositions and methods for treating estrogen-dependent disorders, such as disorders of the female reproductive system, including, inter alia, fibroids and endometriosis. Compounds described herein that may be used to treat such indicators include gonadotropin-releasing hormone (GnRH) antagonists. Suitable GnRH antagonists useful in conjunction with the compositions and methods described herein include thieno[3,4d]pyrimidine derivatives, such as 3-[2-fluoro-5-(2,3-difluoro-6), inter alia. -methoxybenzyloxy)4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4d]pyrimidine-5-carboxylic acid and its choline salts . Using the compositions and methods described herein, the GnRH antagonist can be administered to a patient periodically, such as once or more per day, week, or month, for an extended treatment period, such as a treatment period having a duration of several years. there is. Advantageously, using the compositions and methods of the present disclosure, the GnRH antagonist may be administered to a patient for a prolonged period of treatment without inducing adverse side effects, such as loss of bone mineral density, otherwise known to be a risk associated with GnRH antagonism. can |
| priorityDate | 2019-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 151.